X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (490) 490
humans (485) 485
male (448) 448
prostate cancer (407) 407
abiraterone acetate (369) 369
abiraterone (251) 251
oncology (240) 240
prostatic neoplasms, castration-resistant - drug therapy (192) 192
androgen receptor (163) 163
enzalutamide (153) 153
receptors, androgen - metabolism (153) 153
prostatic neoplasms - drug therapy (151) 151
urology & nephrology (149) 149
increased survival (144) 144
chemotherapy (141) 141
cancer (139) 139
metastasis (133) 133
endocrinology & metabolism (131) 131
androgens (129) 129
antitumor-activity (129) 129
castration (121) 121
animals (117) 117
aged (116) 116
prostatic neoplasms - metabolism (116) 116
docetaxel (115) 115
article (113) 113
antineoplastic agents - therapeutic use (110) 110
care and treatment (109) 109
prostatic neoplasms, castration-resistant - pathology (103) 103
middle aged (102) 102
treatment outcome (99) 99
phenylthiohydantoin - analogs & derivatives (94) 94
castration-resistant prostate cancer (92) 92
prostatic neoplasms - pathology (91) 91
pharmacology & pharmacy (87) 87
prostatic neoplasms, castration-resistant - metabolism (85) 85
survival (85) 85
androgen antagonists - therapeutic use (84) 84
cell line, tumor (78) 78
prostate (78) 78
testosterone (74) 74
aged, 80 and over (73) 73
steroid 17-alpha-hydroxylase - antagonists & inhibitors (72) 72
receptors, androgen - genetics (71) 71
analysis (70) 70
double-blind (70) 70
progression (69) 69
therapy (69) 69
biochemistry & molecular biology (67) 67
resistant prostate-cancer (67) 67
expression (66) 66
disease progression (65) 65
orchiectomy (65) 65
phenylthiohydantoin - therapeutic use (63) 63
research (63) 63
neoplasm metastasis (61) 61
i clinical-trial (60) 60
development and progression (59) 59
androgens - metabolism (57) 57
antineoplastic agents - pharmacology (57) 57
drug resistance, neoplasm (57) 57
men (56) 56
urologic and male genital diseases (56) 56
cyp17 (54) 54
urology (54) 54
metastases (53) 53
prednisone (53) 53
health aspects (52) 52
retrospective studies (51) 51
mitoxantrone plus prednisone (50) 50
antiandrogen (48) 48
mutation (48) 48
signal transduction - drug effects (48) 48
cancer therapies (46) 46
drug therapy (46) 46
medicine & public health (45) 45
disease-free survival (44) 44
plus prednisone (44) 44
prostatic neoplasms - genetics (44) 44
survival analysis (44) 44
cytochrome p-450 (43) 43
mitoxantrone (43) 43
prostatic neoplasms, castration-resistant - genetics (43) 43
steroid 17-alpha-hydroxylase - metabolism (43) 43
androstenes (42) 42
antineoplastic agents, hormonal - therapeutic use (41) 41
inhibitor (41) 41
patients (41) 41
prognosis (41) 41
taxoids - therapeutic use (40) 40
androgen deprivation therapy (39) 39
antineoplastic combined chemotherapy protocols - therapeutic use (39) 39
circulating tumor-cells (39) 39
prostatic neoplasms - surgery (39) 39
tumors (39) 39
splice variants (37) 37
molecular targeted therapy (36) 36
phase-i (36) 36
phase-ii (36) 36
signal transduction (36) 36
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 05/2016, Volume 533, Issue 7604, pp. 547 - 551
Abiraterone blocks androgen synthesis and prolongs survival in patients with castration-resistant prostate cancer, which is otherwise driven by intratumoral... 
ACTIVATION | CYP17A1 INHIBITION | RAT | MULTIDISCIPLINARY SCIENCES | ANDROGEN-RECEPTOR | BIOLOGY | MEN | RESISTANCE | STEROID 5-ALPHA-REDUCTASE | DIHYDROTESTOSTERONE | DEHYDROGENASE | Physiological aspects | Prostate cancer | Care and treatment | Enzymes | Androgens | Metabolites | Oxidation | Metabolism | Gene expression | Steroids
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 03/2018, Volume 124, Issue 6, pp. 1216 - 1224
BACKGROUND Two androgen receptor (AR)‐targeted therapies, enzalutamide and abiraterone acetate plus prednisone (abiraterone), have been approved for the... 
RNA sequencing | androgen receptor | targeted therapies | circulating tumor cells | AR-V7 | CYCLIN D1 | ANDROGEN-DEPRIVATION THERAPY | CIRCULATING TUMOR-CELLS | ONCOLOGY | RNA-SEQ | MEN | CARCINOMA | EXPRESSION | PROGRESSION | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Cyclin D1 - metabolism | Phenylthiohydantoin - therapeutic use | Humans | Middle Aged | Neoplastic Cells, Circulating - metabolism | Male | Smad3 Protein - metabolism | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Abiraterone Acetate - pharmacology | Aged, 80 and over | Biomarkers, Tumor - metabolism | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Phenylthiohydantoin - pharmacology | Prostatic Neoplasms, Castration-Resistant - blood | Androgen Antagonists - pharmacology | Abiraterone Acetate - therapeutic use | Cyclin-Dependent Kinase 6 - metabolism | Prostatic Neoplasms, Castration-Resistant - drug therapy | Cyclin-Dependent Kinase 4 - metabolism | Phenylthiohydantoin - analogs & derivatives | Biomarkers, Tumor - blood | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Androgen Antagonists - therapeutic use | Aged | Protein Kinase Inhibitors - pharmacology | Drug Resistance, Neoplasm - drug effects | Care and treatment | Phenotype | Research | Drug therapy | Prostate cancer | Smad protein | Epithelial cells | Transforming growth factor | Medical services | Smad3 protein | Cyclin D1 | Kinases | CD45 antigen | Metastases | Cell adhesion molecules | Cell adhesion & migration | Gene sequencing | Signal transduction | Transfection | Castration | Cell adhesion | Tumor cells | Medical treatment | Prednisone | Gene expression | Ribonucleic acid--RNA | Patients | Signaling | Mutation | Acetic acid | Prostate | Cancer
Journal Article
Journal of Pharmaceutical and Biomedical Analysis, ISSN 0731-7085, 05/2018, Volume 154, pp. 66 - 74
Abiraterone acetate is administered as a prodrug to patients with metastatic, castration-resistant prostate cancer (mCRPC) and is readily metabolized into the... 
Metabolomics | High-resolution mass spectrometry | Pharmacokinetics | Abiraterone | Prostate cancer | CHEMISTRY, ANALYTICAL | VALIDATION | LC-MS/MS | PHARMACOLOGY & PHARMACY | THERAPIES | RESISTANT PROSTATE-CANCER | ACETATE | ENZALUTAMIDE
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 67, Issue 4, pp. 795 - 802
Journal Article
The Prostate, ISSN 0270-4137, 09/2017, Volume 77, Issue 13, pp. 1373 - 1380
Background To determine the influence of abiraterone Acetate (AA) on neuroendocrine differentiation (NED) in patients with chemotherapy‐naive metastatic... 
neuron‐specific enolase | castration‐resistant prostate cancer | chromogranin A | abiraterone acetate | neuroendocrine differentiation | neuron-specific enolase | castration-resistant prostate cancer | HORMONE-REFRACTORY DISEASE | PLACEBO-CONTROLLED PHASE-3 | SURVIVAL ANALYSIS | ENDOCRINE THERAPY | CHROMOGRANIN-A | MECHANISMS | SERUM-LEVELS | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | CYP17 | ANDROGEN DEPRIVATION THERAPY | Adenocarcinoma - pathology | Neurosecretion - drug effects | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Drug Monitoring - methods | Prostate - metabolism | Prostatic Neoplasms, Castration-Resistant - pathology | Prostate - pathology | Abiraterone Acetate - administration & dosage | Adenocarcinoma - metabolism | China | Antineoplastic Agents - pharmacokinetics | Chromogranin A - metabolism | Neurosecretion - physiology | Retrospective Studies | Abiraterone Acetate - pharmacokinetics | Biomarkers - metabolism | Biomarkers - blood | Prostatic Neoplasms, Castration-Resistant - drug therapy | Adenocarcinoma - drug therapy | Prostatic Neoplasms, Castration-Resistant - metabolism | Prostate-Specific Antigen - blood | Aged | Chromogranin A - blood | Chemotherapy | Metastasis | Prostate cancer | Acetates | Analysis | Cancer | Serum levels | Castration | Acetic acid | Prostate | Phosphopyruvate hydratase | Metastases
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2017, Volume 23, Issue 22, pp. 6812 - 6822
Journal Article
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 66, Issue 5, pp. 815 - 825
Abstract Background Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is approved for treating patients with metastatic... 
Urology | Chemotherapy-naive | Efficacy | Safety | Metastatic castration-resistant prostate cancer | Abiraterone acetate | prostate cancer | Metastatic castration-resistant | PLACEBO | DOCETAXEL CHEMOTHERAPY | PHASE-3 | TRIAL | MITOXANTRONE PLUS PREDNISONE | THERAPY | MEN | UROLOGY & NEPHROLOGY | INCREASED SURVIVAL | LIFE | Neoplasms, Hormone-Dependent - mortality | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms, Castration-Resistant - enzymology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytochrome P-450 Enzyme Inhibitors - adverse effects | Male | Abiraterone Acetate | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Time Factors | Neoplasms, Hormone-Dependent - enzymology | Prednisone - administration & dosage | Androstenes - adverse effects | Double-Blind Method | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Androstenes - administration & dosage | Cytochrome P-450 Enzyme Inhibitors - administration & dosage | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Hormone-Dependent - pathology | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Steroid 17-alpha-Hydroxylase - metabolism | Neoplasms, Hormone-Dependent - drug therapy | Medical colleges | Cancer patients | Care and treatment | Chemotherapy | Corticosteroids | Analysis | Metastasis | Prostate cancer | Acetates | Cancer
Journal Article